ATAI is recognized as the world's leading – and largest – company in the field of psychedelic therapy. KUR-101 will join ATAI's pipeline of ground-breaking mental health interventions such as arketamine and psilocybin, with additional high-impact compounds to be announced soon. Company Contact: Allan Malievsky ATAI Life Sciences Phone: +1 (917) 974-1371 Email: Allan@ATAI.life Investor Contact: Allison Soss KCSA Strategic Communications Phone: +1 (212) 896-1267 Email: ATAI@KCSA.com About ATAI Life Sciences Founded by visionary entrepreneur Christian Angermayer, ATAI Life Sciences AG is a global biotech platform and company builder working to address significant unmet medical needs rooted in a lack of innovation in neuropsychiatry. Based in Berlin, London and New York, its vision is to cure mental health disorders, enabling people to live healthier and happier lives.